Peptide Regulation in 2026: What Actually Changed

Evidence tier: Regulatory. This is a summary of published regulatory positions as of August 2026. Rules differ by jurisdiction, change frequently, and are enforced case by case. For the current status of a specific compound, check the relevant agency directly.

The peptide landscape looks materially different from three years ago, and most of the change happened through three separate mechanisms that are frequently confused with one another: a compounding decision in 2023, a shortage resolution across 2024–25, and an enforcement campaign that escalated sharply in 2026.

Understanding which channel a given compound sits in explains most of what people find confusing about this market.

The four channels

Framework	What it covers
FDA drug approval	Peptides marketed as approved therapeutics — semaglutide, tirzepatide, teriparatide
§503A compounding	Patient-specific prescriptions from state-licensed pharmacies
§503B outsourcing	cGMP bulk compounding for clinics, under FDA registration
Research use only	Non-clinical laboratory reagents, not regulated as medicine

These are legally distinct, and a decision in one doesn't automatically affect the others. That's the single most common source of misreading in coverage of this space.

What the 2023 category-2 designations did

In 2023 the FDA classified a group of peptides as category 2 bulk substances — meaning the agency judged them to raise sufficient safety or efficacy concerns to be inappropriate for §503A compounding. The list included BPC-157, thymosin alpha-1, thymosin beta-4 (TB-500), CJC-1295 and ipamorelin, among others.

The practical effect:

• These compounds became unavailable through legitimate patient-specific compounding
• Clinicians prescribing them through compounding pharmacies had to stop or reroute
• The research-use market was not directly affected — different channel
• Category 2 is not permanent; substances can be reclassified as evidence accumulates

The FDA's reasoning centred on limited safety data, unclear efficacy for compounded formulations, and quality problems in the peptide supply chain. Whether the designations were well-calibrated is genuinely contested in the clinical community. The regulatory position is not ambiguous.

Worth being precise about what this decision was and wasn't. It was a judgment about whether these substances are suitable as raw material for pharmacy compounding. It was not a finding that they are dangerous, and it was not a scheduling action.

The GLP-1 shortage cycle

Separately, the semaglutide and tirzepatide shortages of 2022–24 opened a window during which compounding pharmacies could legally prepare copies. Demand was enormous, and a large share of the US compounded-peptide industry pivoted to serve it.

Date	Event
2022	Both drugs placed on the FDA shortage list
2023	Compounded GLP-1 market expands rapidly; scrutiny increases
Oct 2024	Tirzepatide shortage declared resolved
Dec 2024	Tirzepatide compounding wind-down begins
Feb 2025	Semaglutide shortage declared resolved
2025	Litigation between compounders and FDA over wind-down timelines
Late 2025–2026	Wind-downs conclude; broad replication no longer permitted

Patient-specific compounding for genuine individualised clinical reasons — documented allergy, an atypical dose — remains possible in principle. The large-scale "compounded semaglutide, $X a month" telehealth model does not. The broader pharmacology of these drugs is covered in our piece on GLP-1 agonists and metabolic flexibility.

This was never a ban. It was the expiry of a temporary allowance that existed only because of the shortage.

What escalated in 2026

The newer development, and the one changing the practical landscape fastest, is enforcement around retatrutide.

Retatrutide is an investigational triple agonist in Phase 3 trials with no approval anywhere. Because it's a biologic with no approved active ingredient, it falls outside the compounding pathway entirely — there is no shortage-style loophole available. We cover the trial data in detail in our retatrutide Phase 3 readout.

In June 2026 the FDA stated that sales of unapproved retatrutide to consumers are illegal and that it cannot lawfully be compounded, describing research-use-only products in this category as being of unknown quality.

In August 2026 Eli Lilly filed six lawsuits against US entities selling retatrutide, targeting compounding pharmacies, medical spas and online sellers. The specific allegation in several was that the "research use only" label was a fiction and the product was intended for human use. Lilly stated it had referred more than 200 entities to the FDA, the Department of Justice, state attorneys general and licensing boards, and had identified over 14,000 websites, adverts and listings across more than 100 countries. It also publicly called on payment processors, e-commerce platforms and logistics companies to withdraw service from these sellers.

The significance for the wider market isn't about retatrutide specifically. It's that the RUO designation is now being tested in court as a factual claim rather than accepted as a labelling formality. That's a change in how the channel works, and it will likely outlast this particular compound.

The research-use channel, honestly described

RUO peptides occupy a genuinely distinct legal space. They are laboratory reagents, not medicines. Regulatory constraints are much lighter and quality controls, where they exist, are voluntary.

For actual research applications — in vitro work, animal studies — the channel is legitimate and necessary. For human use it is neither approved nor endorsed by any regulatory authority anywhere.

The uncomfortable reality is that the channel serves both a real research need and a large de facto consumer market it was never designed for. That ambiguity is unlikely to resolve through either full legalisation or full prohibition. The more probable path is what's happening now: continued grey-zone operation with periodic enforcement against whoever is most visibly treating the label as decorative.

What separates documented suppliers from the rest

Whatever the channel, the documentation that makes material suitable for reproducible work is consistent:

• Third-party HPLC purity analysis, per lot
• Mass-spectrometry identity confirmation, per lot
• Endotoxin testing, per lot
• Documented supply chain for the active ingredient
• Certificates issued against each batch, not a single generic document

Material without a lot-specific certificate isn't usable for reproducible research, because you cannot know what produced your result. Independent testing across this market has repeatedly found label mismatches — wrong purity, wrong concentration, occasionally wrong compound. Contradictory findings in the informal literature often reflect vial contents rather than pharmacology.

Outside the United States

Jurisdiction	Framework	Notes
UK	MHRA; Human Medicines Regulations 2012; Section 10 exemption for pharmacy preparation	Advertising an unlicensed medicinal product is itself an offence, separate from supply
EU	EMA approval; national compounding rules	Practice varies considerably by member state
Australia	TGA scheduling; most peptides Schedule 4	Strict prescription requirements
Canada	Health Canada; Natural Health Products framework for some	Distinct from the US structure

The UK detail is worth pulling out because it's frequently missed. Under the Human Medicines Regulations 2012, advertising an unlicensed medicinal product is a separate offence from supplying one. Unlicensed medicine supply carries up to two years' imprisonment and unlimited fines, with personal director liability under Regulation 338. The MHRA's jurisdiction turns substantially on presentation and intended use — meaning how a product is described can determine whether it's a medicine, independent of what's in the vial.

The direction of travel across all four jurisdictions is broadly consistent: increasing scrutiny of grey markets, preserved space for legitimate individualised compounding, and rapid response when a new peptide class attracts public attention.

What hasn't changed

Several categories are unaffected by any of the above:

• Approved peptide therapeutics continue to be prescribed and dispensed normally
• Patient-specific compounding remains available for peptides still on the eligible bulks lists
• Genuine laboratory research use is unaffected by compounding decisions
• Clinical trials of investigational peptides continue under IND

The tightening has landed almost entirely on the middle ground — compounds being prescribed and marketed as though they were established therapeutics without the clinical evidence to support that framing.

Where the evidence stands

Question	Status	Confidence
Category-2 restricts §503A compounding	Established regulation	High
Broad compounded GLP-1 replication ended	Established as of 2026	High
Patient-specific compounding preserved	Yes, narrower bulks list	High
RUO channel legally distinct from clinical	Yes	High
RUO peptide quality varies substantially	Well documented	High
RUO framing being tested in litigation	Active, unresolved	Moderate
Long-term regulatory direction	More restriction on replication and grey-market ambiguity	Moderate

Editorial perspective

The 2023–26 cycle reads as a course correction rather than a crackdown, with one caveat that's getting sharper.

The pre-2023 environment had a real problem. A substantial category of peptides was being prescribed and marketed as established therapy on the strength of preclinical mechanism and a handful of small human studies. That's a gap between claim and evidence, and tightening was a predictable response.

The category-2 process isn't perfect. Some affected peptides have more legitimate clinical evidence than the designation implies, and the reclassification route is opaque. It's coherent to disagree with specific decisions while accepting that some correction was overdue.

The 2026 enforcement wave is a different kind of event. The 2023 and 2024–25 actions were regulatory adjustments. What's happening now is a manufacturer, with far greater resources than any regulator applies to this space, systematically litigating against the RUO framing itself and lobbying the payment and logistics infrastructure to withdraw. That has a different mechanism and a different reach, and it doesn't require a rule change to alter what's practically possible.

For anyone following this: track the specific bulks-list status of any compound of interest, be clear about which channel you're actually engaging with, and treat analytical documentation as the first-line quality check rather than a nice-to-have.

What to watch

• Whether a workable process emerges for reclassifying category-2 peptides as evidence accumulates
• Clearer disclosure standards for telehealth clinics offering compounded peptides
• Post-market safety surveillance for the compounded-GLP-1 wind-down cohort
• Whether the retatrutide litigation produces a precedent on what "research use only" means as a factual claim
• International harmonisation of research-peptide labelling standards

Frequently asked

---